Tango combo clears Rasonque bar and Takeda's Innovent sees early returns as ESMO data leaks dampen hype

The first day of the European Society for Medical Oncology (ESMO) congress opened in Madrid with several notable updates from the oncology field.

Tango's combination therapy cleared the Rasonque regulatory bar, a milestone that allows the product to move forward in its development pathway.

Takeda's investment in Innovent began to show early financial returns, suggesting the partnership is delivering value sooner than expected.

Meanwhile, anticipation among attendees cooled after leaked data on Moderna and Merck's cancer vaccine projects were reported, tempering the overall excitement at the meeting.